Article
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
The Journal of antimicrobial chemotherapy - 1 Sept 2020
Blanch-Lombarte Oscar, Santos José R, Peña Ruth, Jiménez-Moyano Esther, Clotet Bonaventura, Paredes Roger, Prado Julia G
Abstract excerpt
BACKGROUND: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. METHODS: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.